In recent trading session, Edwards Lifesciences Corp (NYSE:EW) saw 0.73 million shares changing hands at last check today with its beta currently measuring 1.12. Company’s recent per share price level of $77.25 trading at $0.28 or 0.36% at last check today assigns it a market valuation of $45.31B. That most recent trading price of EW’s stock is at a discount of -23.3% from its 52-week high price of $95.25 and is indicating a premium of 23.72% from its 52-week low price of $58.93. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.95 million shares which gives us an average trading volume of 4.53 million if we extend that period to 3-months.
For Edwards Lifesciences Corp (EW), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.19. Splitting up the data highlights that, out of 17 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 14 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.62 in the current quarter.
Edwards Lifesciences Corp (NYSE:EW) trade information
Upright in the green today for gaining 0.36%, in the last five days EW remained trading in the green while hitting it’s week-highest on Thursday, 06/26/25 when the stock touched $77.25 price level, adding 0.39% to its value on the day. Edwards Lifesciences Corp’s shares saw a change of -14.33% in year-to-date performance and have moved 4.42% in past 5-day. Edwards Lifesciences Corp (NYSE:EW) showed a performance of 1.35% in past 30-days. Number of shares sold short was 6.07 million shares which calculate 1.39 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 75 to the stock, which implies a fall of -3.0% to its recent value today. Analysts have been projecting 74 as a low price target for the stock while placing it at a high target of 90. It follows that stock’s current price would jump 4.21% in reaching the projected high whereas dropping to the targeted low would mean a gain of 4.21% for stock’s current value.
Edwards Lifesciences Corp (EW) estimates and forecasts
This year revenue growth is estimated to rise 8.32% from the last financial year’s standing.
26 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.49B for the same. And 25 analysts are in estimates of company making revenue of 1.47B in the next quarter. Company posted 1.63B and 1.35B of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.36% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 1.67% while estimates for its earnings growth in next 5 years are of 8.56%.
Edwards Lifesciences Corp (NYSE:EW)’s Major holders
Insiders are in possession of 0.92% of company’s total shares while institution are holding 89.48 percent of that, with stock having share float percentage of 90.30%. Investors also watch the number of corporate investors in a company very closely, which is 89.48% institutions for Edwards Lifesciences Corp that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at EW for having 53.58 million shares of worth $4.95 billion. And as of 2024-06-30, it was holding 8.8982 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 50.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.4663 of outstanding shares, having a total worth of $4.71 billion.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 18.63 shares of worth $1.44 billion or 3.18% of the total outstanding shares. The later fund manager was in possession of 18.39 shares on Jan 31, 2025 , making its stake of worth around $1.42 billion in the company or a holder of 3.14% of company’s stock.
